Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $33.00.

A number of research analysts recently issued reports on AVTX shares. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $23.00 price objective on the stock. BTIG Research started coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 target price for the company. Finally, Piper Sandler began coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its position in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP purchased a new position in Avalo Therapeutics during the 4th quarter valued at about $114,000. Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at about $145,000. Northern Trust Corp purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth approximately $168,000. Finally, Bank of Montreal Can acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Stock Up 4.4 %

NASDAQ:AVTX opened at $8.73 on Tuesday. The stock has a 50 day moving average of $7.59 and a 200-day moving average of $9.13. Avalo Therapeutics has a 52 week low of $5.99 and a 52 week high of $34.46.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.